Bio-Rad Laboratories, Inc. (BIO-B)
- Previous Close
279.91 - Open
281.55 - Bid 276.05 x 1400
- Ask 286.14 x 800
- Day's Range
279.91 - 281.55 - 52 Week Range
271.00 - 467.95 - Volume
5 - Avg. Volume
275 - Market Cap (intraday)
7.882B - Beta (5Y Monthly) 0.88
- PE Ratio (TTM)
-- - EPS (TTM)
-21.83 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets. It also designs, manufactures, markets, and supports test systems, informatics systems, test kits, and specialized quality controls for hospitals, diagnostic reference, transfusion, and physician office laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
www.bio-rad.comRecent News: BIO-B
Performance Overview: BIO-B
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BIO-B
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BIO-B
Valuation Measures
Market Cap
7.88B
Enterprise Value
7.68B
Trailing P/E
--
Forward P/E
25.13
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.06
Price/Book (mrq)
0.91
Enterprise Value/Revenue
2.88
Enterprise Value/EBITDA
-11.73
Financial Highlights
Profitability and Income Statement
Profit Margin
-23.86%
Return on Assets (ttm)
1.77%
Return on Equity (ttm)
-6.94%
Revenue (ttm)
2.67B
Net Income Avi to Common (ttm)
-637.32M
Diluted EPS (ttm)
-21.83
Balance Sheet and Cash Flow
Total Cash (mrq)
1.61B
Total Debt/Equity (mrq)
16.08%
Levered Free Cash Flow (ttm)
170.82M